Unraveling Molecular Networks in Thymic Epithelial Tumors: Deciphering the Unique Signatures

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Oct 18

PMID 37849766

Authors

Xiao Zhang

Pengpeng Zhang

Ansheng Cong

Yanlong Feng

Hao Chi

Zhijia Xia

Hailin Tang

Affiliations

Soon will be listed here.

Abstract

Thymic epithelial tumors (TETs) are a rare and diverse group of neoplasms characterized by distinct molecular signatures. This review delves into the complex molecular networks of TETs, highlighting key aspects such as chromosomal abnormalities, molecular subtypes, aberrant gene mutations and expressions, structural gene rearrangements, and epigenetic changes. Additionally, the influence of the dynamic tumor microenvironment on TET behavior and therapeutic responses is examined. A thorough understanding of these facets elucidates TET pathogenesis, offering avenues for enhancing diagnostic accuracy, refining prognostic assessments, and tailoring targeted therapeutic strategies. Our review underscores the importance of deciphering TETs' unique molecular signatures to advance personalized treatment paradigms and improve patient outcomes. We also discuss future research directions and anticipated challenges in this intriguing field.

Citing Articles

The role of tumor-associated macrophages in lung cancer.

Zhu R, Huang J, Qian F Front Immunol. 2025; 16:1556209.

PMID: 40079009 PMC: 11897577. DOI: 10.3389/fimmu.2025.1556209.

Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived Dimethylaminomicheliolide and Micheliolide.

Li J, Li X, Liu H Front Pharmacol. 2025; 16:1551115.

PMID: 40051564 PMC: 11882563. DOI: 10.3389/fphar.2025.1551115.

Peng J, Tong L, Liang R, Yan H, Jiang X, Dai Y Int J Genomics. 2025; 2025:5595391.

PMID: 40008397 PMC: 11858721. DOI: 10.1155/ijog/5595391.

Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment.

Shu Y, Li J Front Immunol. 2025; 16:1526296.

PMID: 39949776 PMC: 11821639. DOI: 10.3389/fimmu.2025.1526296.

Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis.

Wang A, Yan S, Jiang W, Chen X, Huang Y, Zu X BMC Cancer. 2025; 25(1):211.

PMID: 39920578 PMC: 11804071. DOI: 10.1186/s12885-025-13537-x.

References

Wheler J, Hong D, Swisher S, Falchook G, Tsimberidou A, Helgason T . Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013; 4(6):890-8. PMC: 3757246. DOI: 10.18632/oncotarget.1015. View

Marx A, Porubsky S, Belharazem D, Saruhan-Direskeneli G, Schalke B, Strobel P . Thymoma related myasthenia gravis in humans and potential animal models. Exp Neurol. 2015; 270:55-65. DOI: 10.1016/j.expneurol.2015.02.010. View

Ji G, Ren R, Fang X . Identification and Characterization of Non-Coding RNAs in Thymoma. Med Sci Monit. 2021; 27:e929727. PMC: 8268976. DOI: 10.12659/MSM.929727. View

Nicoli V, Coppede F . Epigenetics of Thymic Epithelial Tumors. Cancers (Basel). 2023; 15(2). PMC: 9856807. DOI: 10.3390/cancers15020360. View

Mokhtar M, Kondo K, Namura T, Ali A, Fujita Y, Takai C . Methylation and expression profiles of MGMT gene in thymic epithelial tumors. Lung Cancer. 2014; 83(2):279-87. DOI: 10.1016/j.lungcan.2013.12.004. View

Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez J . Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. Cancer Res. 2017; 77(20):5614-5627. PMC: 8170838. DOI: 10.1158/0008-5472.CAN-17-1323. View

Cho J, Kim H, Ku B, Choi Y, Cristescu R, Han J . Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2018; 37(24):2162-2170. DOI: 10.1200/JCO.2017.77.3184. View

Kelly R . Systemic treatment of advanced thymic malignancies. Am Soc Clin Oncol Educ Book. 2014; :e367-73. DOI: 10.14694/EdBook_AM.2014.34.e367. View

Machens A, Loliger C, Pichlmeier U, Emskotter T, Busch C, Izbicki J . Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol. 1999; 91(3):296-301. DOI: 10.1006/clim.1999.4710. View

10.

Xia Y, Liao W, Huang S, Liu Z, Huang X, Yang C . Nomograms for Predicting the Overall and Cancer-Specific Survival of Patients with High-Grade Glioma: A Surveillance, Epidemiology, and End Results Study. Turk Neurosurg. 2019; 30(1):48-59. DOI: 10.5137/1019-5149.JTN.26131-19.2. View

11.

Yamamoto Y, Iwahori K, Funaki S, Matsumoto M, Hirata M, Yoshida T . Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors. Sci Rep. 2020; 10(1):4064. PMC: 7055333. DOI: 10.1038/s41598-020-61053-8. View

12.

Zhuang J, Guan M, Liu M, Liu Y, Yang S, Hu Z . Immune-Related Molecular Profiling of Thymoma With Myasthenia Gravis. Front Genet. 2021; 12:756493. PMC: 8580862. DOI: 10.3389/fgene.2021.756493. View

13.

Conforti F, Zucali P, Pala L, Catania C, Bagnardi V, Sala I . Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23(10):1287-1296. DOI: 10.1016/S1470-2045(22)00542-3. View

14.

Massoth L, Hung Y, Dias-Santagata D, Onozato M, Shah N, Severson E . Pan-Cancer Landscape Analysis Reveals Recurrent - Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO Precis Oncol. 2020; 4. PMC: 7446345. DOI: 10.1200/PO.19.00288. View

15.

Padda S, Gokmen-Polar Y, Hellyer J, Badve S, Singh N, Vasista S . Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. Oncotarget. 2021; 12(12):1178-1186. PMC: 8202771. DOI: 10.18632/oncotarget.27978. View

16.

Weis C, Yao X, Deng Y, Detterbeck F, Marino M, Nicholson A . The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol. 2015; 10(2):367-72. PMC: 4318643. DOI: 10.1097/JTO.0000000000000393. View

17.

Rajan A, Carter C, Berman A, Cao L, Kelly R, Thomas A . Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014; 15(2):191-200. PMC: 3954701. DOI: 10.1016/S1470-2045(13)70596-5. View

18.

Iaiza A, Tito C, Ianniello Z, Ganci F, Laquintana V, Gallo E . METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors. Clin Epigenetics. 2021; 13(1):173. PMC: 8447796. DOI: 10.1186/s13148-021-01159-6. View

19.

Umemura S, Zhu J, Chahine J, Kallakury B, Chen V, Kim I . Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors. Lung Cancer. 2020; 147:221-228. DOI: 10.1016/j.lungcan.2020.07.018. View

20.

Petrini I, Meltzer P, Zucali P, Luo J, Lee C, Santoro A . Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis. 2012; 3:e351. PMC: 3406591. DOI: 10.1038/cddis.2012.92. View